A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers

Investigational New Drugs
Aflah RoohullahLisa G Horvath

Abstract

Background The MET tyrosine kinase and its ligand, hepatocyte growth factor (HGF) also known as scatter factor, are associated with tumourigenesis and metastasis by promotion of scattering, proliferation, angiogenesis, motility and invasion. ASLAN-002 is a potent inhibitor of MET as well as related kinases. A phase I dose escalation study was conducted to determine the safety and pharmacokinetics of ASLAN-002 in patients with advanced cancer. Methods Patients with advanced or metastatic solid tumours, who had progressed on standard therapy or for whom standard therapy was not known, were administered ASLAN-002 orally. The starting dose was 100 mg once daily (QD) with subsequent cohorts to receive doses of 200 mg QD, 300 mg QD, 450 mg QD, 600 mg QD, 300 mg twice daily (BID), 450 mg BID, and 600 mg BID. Results Forty patients were included across 7 dose cohorts. Cohort 8 (600 mg BID) was not opened due to the lack of appreciable pharmacokinetic (PK) differences between 300 mg BID and 450 mg BID and higher incidences of grade 3 or 4 adverse events (AE) in Cohort 7 (450 mg BID). Fifteen patients (37.5%) experienced a grade 3 or 4 AE. The most commonly reported AEs were nausea (55%), fatigue (47.5%) and constipation (30%). One dose ...Continue Reading

References

Jul 4, 2007·Journal of Cellular Physiology·Silvia Benvenuti, Paolo M Comoglio
Dec 1, 2011·Therapeutic Advances in Medical Oncology·J Rafael Sierra, Ming-Sound Tsao
May 2, 2012·Investigational New Drugs·Jeffrey R InfanteRamesh K Ramanathan
Aug 8, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·George R BlumenscheinAna M Gonzalez-Angulo
Nov 22, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David C SmithMaha Hussain
Jan 5, 2014·Pharmacology & Therapeutics·Christiane R Maroun, Tracey Rowlands
Oct 4, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·L Rhoda MolifeMalcolm Richard Ranson
Dec 4, 2014·The New England Journal of Medicine·Benjamin J SolomonUNKNOWN PROFILE 1014 Investigators
Mar 7, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Martijn P LolkemaFerry A L M Eskens
Sep 26, 2015·The New England Journal of Medicine·Toni K ChoueiriUNKNOWN METEOR Investigators
Jul 13, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew SmithKarim Fizazi
Jul 28, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Tony Shu Kam MokKeunchil Park
Dec 13, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David R SpigelTony Mok
Oct 21, 2014·Biomedicines·Simona GalloTiziana Crepaldi

❮ Previous
Next ❯

Citations

Dec 1, 2019·Expert Opinion on Investigational Drugs·Helena OliveresJoan Maurel
Dec 2, 2020·British Journal of Cancer·Derek DustinSuzanne A W Fuqua
Jan 20, 2021·Clinical and Translational Medicine·Neng WangZhiyu Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.